Abciximab (Reopro) for acute ischaemic stroke - horizon scanning review
NHSC
Record ID 32005000245
English
Authors' objectives:
This study aims to assess the effectiveness of abciximab (Reopro) for acute ischaemic stroke.
Authors' recommendations:
Abciximab (Reopro) is a platelet glycoprotein IIb/IIIa inhibitor in phase III trials for patients with acute ischaemic stroke within 6 hours of symptom onset or patients who wake-up with symptoms. A randomised, double-blind, placebo-controlled, phase II trial has shown improved functional outcome in patients treated with abciximab within 6 hours of symptom onset. A randomised, dose-escalation, phase II trial found no cases of major intracranial haemorrhage. A phase III, randomised, double-blind, placebo-controlled trial is ongoing to examine the use of abciximab in patients presenting within 5 hours of symptom onset, 5-6 hours of treatment onset and those awakening with stroke symptoms and are treated within 3 hours.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Acute Disease
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Brain Ischemia
- Stroke
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.